Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series

Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR)(+), human epidermal growth factor receptor (HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Schettini, Francesco, Santo, Irene De, Rea, Carmen G., Viggiani, Martina, Buono, Giuseppe, Angelis, Carmine De, Cardalesi, Cinzia, Lauria, Rossella, Giuliano, Mario, Forestieri, Valeria, Thomas, Guglielmo, Maione, Pierfrancesco, Limite, Gennaro, Accurso, Antonello, Malorni, Luca, Placido, Sabino De, Arpino, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087462/
https://www.ncbi.nlm.nih.gov/pubmed/32257203
http://dx.doi.org/10.3892/mco.2020.2016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087462/
https://www.ncbi.nlm.nih.gov/pubmed/32257203
http://dx.doi.org/10.3892/mco.2020.2016

Ejemplares similares